Clinical trial
Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in…
NCT00317395 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00317395 |
|---|---|
| Title | Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome |
| Official title | A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy |
| Acronym | SEPIA-ACS1 |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Disease |
| Intervention type | Drug |
| Interventions | Otamixaban (XRP0673), unfractionated heparin, eptifibatide |
| Enrollment | 3,241 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Apr 24, 2006 |
| Last update posted | Dec 3, 2014 |
| Countries | Argentina, Austria, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland and 24 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: